High-risk outpatient RCT with 931 peginterferon lambda patients and 1,018 control patients, showing significantly lower hospitalization/ER visits with treatment. Single subcutaneous injection.There were 85/931 and 286/1018 patients for which baseline SARS-CoV-2 status was unknown, p = 1.4e-27 (about 1 in 704 septillion).The most frequent risk factors were more common in the placebo group, for example obesity 39.1% control vs. 34.5% treatment, p = 0.04.Authors claim patients were unaware or the randomization assignments, however some patients received oral placebo in a trial of a treatment requiring subcutaneous injection.The numbers in Table 1 and Table S1 do not match, e.g., the text and Table 1 indicate 931 ITT interferon patients, while Table S1 shows 916.All deaths in the placebo arm were attributed to COVID-19, while only 50% were in the interferon arm. One placebo death is listed as both due to COVID-19 and due to acute myeloid leukemia (Table S6).Other arms of this trial show many critical issues [Reis], many of which may also apply to this arm.See also [Kelleni].